Black Diamond Therapeutics is seeking partners to develop silevertinib for the treatment of Glioblastoma Multiforme (GBM).
2 reports, 2 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Black Diamond Therapeutics is seeking partners to develop silevertinib for the treatment of Glioblastoma Multiforme (GBM).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
GBM
South Korean esports player
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksIs the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX? Black Diamond Therapeutics, Inc.’s BDTX lead pipeline candidate, silevertinib, is a brain penetrant, fourth-generation epidermal gro
- Simply Wall St.Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors As the major U.S. stock indices hover near record highs following two consecutive weeks of gains, investors are closely mon